| 中文名称: | CAY10404 | ||||
|---|---|---|---|---|---|
| 英文名称: | CAY10404 | ||||
| CAS No: | 340267-36-9 | 分子式: | C17H12F3NO3S | 分子量: | 367.34 |
| CAS No: | 340267-36-9 | ||||
| 分子式: | C17H12F3NO3S | ||||
| 分子量: | 367.34 | ||||
基本信息
|
产品编号： |
C10838 |
||||
|
产品名称： |
CAY10404 |
||||
|
CAS: |
340267-36-9 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
|
||||
|
分子式： |
溶于液体 |
-80℃ |
两年 |
||
|
分子量 |
367.34 |
-20℃ |
一个月 |
||
|
化学名： |
3-[4-(Methylsulfonyl)phenyl]-4-phenyl-5-(trifluoromethyl)-isoxazole |
||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
100mg/mL(272.23mM;Need ultrasonic) |
|||
|
Ethanol |
|
||||
|
Water |
|
||||
|
体内(现配现用): |
1.请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80→45% saline，Solubility:2.5mg/mL(6.81mM);Suspended solution; Need ultrasonic |
||||
|
此⽅案可获得2.5mg/mL(6.81mM)的均匀悬浊液，悬浊液可⽤于⼝服和腹腔注射。以1mL⼯作液为例，取100μL25.0mg/mL的澄清DMSO储备液加到400μLPEG300中，混合均匀；向上述体系中加⼊50μLTween-80，混合均匀；然后继续加⼊450μL⽣理盐⽔定容⾄1mL。 |
|||||
|
2.请依序添加每种溶剂：10% DMSO→90% (20% SBE-β-CD in saline) Solubility:2.5mg/mL(6.81mM);Suspended solution; Need ultrasonic |
|||||
|
此⽅案可获得2.5mg/mL(6.81mM)的均匀悬浊液，悬浊液可⽤于⼝服和腹腔注射。以1mL⼯作液为例，取100μL25.0mg/mL的澄清DMSO储备液加到900μL20%的SBE-β-CD⽣理盐⽔⽔溶液中，混合均匀。 |
|||||
|
3.请依序添加每种溶剂：10% DMSO→90% corn oil Solubility:≥2.5mg/mL(6.81mM);Clear solution |
|||||
|
此⽅案可获得≥2.5mg/mL(6.81mM，饱和度未知)的澄清溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。以1mL⼯作液为例，取100μL25.0mg/mL的澄清DMSO储备液加到900μL⽟⽶油中，混合均匀。 |
|||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
2.7223mL |
13.6114mL |
27.2227mL |
|
5mM |
0.5445mL |
2.7223mL |
5.4445mL |
|
10mM |
0.2722mL |
1.3611mL |
2.7223mL |
生物活性
|
产品描述 |
一种有效且高度选择性的环氧合酶2(COX-2)抑制剂，IC50为1nM，选择性指数(SI；COX-1IC50/COX-2IC50)为>500000。 |
||
|
靶点 |
COX-2 1nM(IC50) |
COX-1 >500μM(IC50) |
Akt |
|
体外研究 |
CAY10404 (compound 7) exhibits no inhibition of COX-1 (IC50>500µM) CAY10404 (10-100µM; for 3 days) inhibits the growth of NSCLC cell lines in a concentration-dependent manner and has an average 50% inhibitory concentration (IC50) of 60-100µM CAY10404 (20-100µM; for 3 days) induces apoptosis in NSCLC cells CAY10404 (80µM; for 3 days) induces a concentration-dependent decrease in the level of the anti-apoptotic proteins (Bcl-2 and Bcl-XL) and pAkt and pGSK-3β CAY10404 (20, 50, 80, 100µM; for 14 days) compromises the ability of H460 cells to form colonies in anchorage-independent growth in a concentration-dependent manner Cell Viability Assay |
||
|
Cell Line: |
Non-small cell lung cancer (NSCLC) cells (H1703, H358, H460) |
||
|
Concentration: |
10-100µM |
||
|
Incubation Time: |
For 3 days |
||
|
Result: |
Inhibited the growth of NSCLC cell lines in a concentration-dependent manner. |
||
|
Apoptosis Analysis |
|||
|
Cell Line: |
H460 cells |
||
|
Concentration: |
20, 50, 100µM |
||
|
Incubation Time: |
For 3 days |
||
|
Result: |
Induced apoptosis. |
||
|
Western Blot Analysis |
|||
|
Cell Line: |
NSCLC cells (H358, H460) |
||
|
Concentration: |
80µM |
||
|
Incubation Time: |
For 3 days |
||
|
Result: |
Induced a concentration-dependent decrease in the level of the anti-apoptotic proteins (Bcl-2 and Bcl-XL) and pAkt and pGSK-3β, without changing the level of the pro-apoptotic protein (Bax) and total Akt and GSK-3β protein levels. |
||
|
体内研究 |
CAY10404 (50 mg/kg/day; ip; for 4 days) decreases lung inflammation in HTV mice and attenuates ventilator-induced lung injury |
||
|
Animal Model: |
Adult male C57Bl/6J mice weighing 24-30 g |
||
|
Dosage: |
50 mg/kg |
||
|
Administration: |
IP; daily; for 4 days |
||
|
Result: |
Attenuated cyclooxygenase activity, significantly decreasing BAL PGE2 and 6-keto PGF1α. |
||
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
